Medtronic Agrees To Settle Infuse Shareholder Suit
Executive Summary
Device manufacturer Medtronic has offered to pay $43m to resolve a lawsuit brought by shareholders. The suit, filed in 2013, claimed that the company defrauded investors via deceptive marketing for its Infuse bone graft product.